Why the study?
RYR1 variants contribute to rhabdomyolysis events not directly related to anesthesia in otherwise healthy individuals, representing a multidisciplinary condition with various triggers, presentations, and therapeutic considerations.
Design
Review
Authors
Loading...
May support RYR1 testing in recurrent rhabdomyolysis; leaves open dantrolene efficacy pending prospective trials.
RYR1 variants should be considered in patients with recurrent or severe rhabdomyolysis, and dantrolene may offer a targeted therapeutic option.
Kruijt et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: